LTR Pharma's nasal spray for Erectile Dysfunction (ED) Spontan is now available to patients under the TGA's Authorised Prescriber Scheme (APS).
The move follows Spontan's first prescriptions dispensed via the TGA's Special Access Scheme earlier this month.
The APS allows medical practitioners to prescribe Spontan more broadly to ED patients, offering a streamlined alternative to the case-by-case approval process required under the Special Access Scheme.
The development paves the way for easier patient access to the medication in Australia.
Leading the initial APS prescriptions is LTR's Chief Scientific Advisor and urologist Prof Eric Chung, whose involvement signals growing recognition of Spontan's potential in addressing unmet needs for ED.
"The Authorised Prescriber Scheme enables us to offer Spontan to a wider range of patients," commented Chung.
"Its rapid onset could greatly enhance quality of life for men with ED, providing a spontaneous treatment option."
LTR Pharma Chairman, Lee Rodne, said, "the authorisation represents an important milestone for LTR Pharma, as the scheme enables authorised healthcare professionals to obtain meaningful, hands-on experience with Spontan in real-world settings". JG
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Aug 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Aug 24
